Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Azacitidine in Refractory/Relapsed AML
NCT02953561Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2017
- Primary completion
- Sep 2019
- Countries
- 1
01
Overview
Phase 2, open-label trial of avelumab in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose and Dose Limiting Toxicity at 28 days. Started Feb 2017; status: terminated.
02
Drugs
avelumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02953561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953561.